New diabetes pill shows promise in early safety trial

NCT ID NCT06869018

Completed Disease control Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new oral drug called LY3549492 in 92 Japanese volunteers, some with type 2 diabetes and some healthy. The main goal was to check safety and how the body processes the drug. Participants took multiple doses over several weeks, and researchers monitored side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY3549492 (oral drug)
What this could lead to: If successful, this could lead to a new oral medication to help control blood sugar in people with type 2 diabetes.
What could go wrong: This is an early Phase 1 trial focused on safety, not effectiveness. The drug may not work as hoped or could have side effects. Results may not apply to non-Japanese populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus endocrine system disorder glucose metabolism disease metabolic disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY TYPE 2 DIABETES MELLITUS (T2D)

Contacts and locations

Locations

Clinical Research Hospital Tokyo

Shinjuku-ku, 160-0004, Japan
Hakata Clinic

Fukuoka, 812-0025, Japan
Medical Corporation Heishinkai OPHAC Hospital

Osaka, 532-0003, Japan
P-One Clinic

Hachiōji, 192-0071, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.